Several studies have documented the involvement of the ligand PRL in the growth control of different tumors such as breast [39], liver [40] and prostate [41] and further, PRL antagonists such as hPRL-G129R has been demonstrated to inhibit breast cancer growth in vitro and in vivo [42]. Here, PRL is linked to breast cancer.